Ehningen/Gothenburg (ots) - Bertrandt continues its international growth strategy by founding Bertrandt Sverige AB in Sweden. Proximity to renowned OEMs such as Volvo Cars, access to an innovation cluster, and a focus on sustainable, future-oriented technologies are the core of this location decision. “Unlock the Swedish potential” – under this guiding principle, ...
NTT DATA Business Solutions AG
LAUDA DR. R. WOBSER GMBH & CO. KG
Asklepios Kliniken GmbH & Co. KGaA
Wiesbaden, Germany (ots) - - Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy - One of the world’s most highly endowed medical prizes, with €1 million in prize money, awarded for the first time - Titia große Broermann: “With the Broermann Medical Innovation Award, we want to make outstanding medical ...
LAUDA DR. R. WOBSER GMBH & CO. KG
Europäischer Rechnungshof - European Court of Auditors
Kvietimas žiniasklaidai 2025 m. spalio 27 d. Ar ekonomikai gaivinti po COVID‑19 pandemijos skirti milijardai pagerino ES verslo aplinką? - Virtuali spaudos konferencija: spalio 27 d. (pirmadienį) 10.00 val. CET - ...
LAUDA DR. R. WOBSER GMBH & CO. KG
Vienna (ots) - University of Vienna has improved from rank 110 to 95 The University of Vienna ranks 95th in this year's THE World University Rankings, making it the first Austrian university to be listed among the top 100 universities worldwide. It excelled in the categories of research, internationalisation, teaching, and industry engagement, despite increasing global ...
Asklepios Kliniken GmbH & Co. KGaA
LAUDA DR. R. WOBSER GMBH & CO. KG
Hanover/Beijing/Singapore (ots) - ● NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people ● Syntellix‘ product approval for China is the largest and most important success in the company’s history; product approval in China was the company’s ...
LAUDA DR. R. WOBSER GMBH & CO. KG
Brussels (ots/PRNewswire) - Results for the first half year ended 30 June 2025 Financial highlights Solid business performance and improved operating margin despite challenging geopolitical and macroeconomic environment - Underlying1 business income for H1 2025 reached €932 million, an 8% increase compared to H1 2024. Higher safekeeping revenues, supported by an increase in group depot and in settlement and ...
medac Gesellschaft für klinische Spezialpräparate mbH
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
